TP53 and B-cell non-Hodgkin lymphoma: The results revealed that B-cell lymphoma patients with both wild-type TP53 and Hippo pathways had the best prognosis, while the patients with the presence of co-mutated TP53 and Hippo pathways had the worst PFS (P<0.0001, Supplementary Figure 3).